InnFocus releases clinical results on MicroShunt implant

Article

InnFocus, Inc. recently reported on a series of 43 glaucoma patients (n=34, 22, and 17 at one, two, and three years, respectively) treated with its MicroShunt implant.

Nice, France-InnFocus, Inc. recently reported on a series of 43 glaucoma patients (n=34, 22, and 17 at one, two, and three years, respectively) treated with its MicroShunt implant.

According to the company, the average intraocular pressure (IOP) reduction from medicated baseline (23.6 mmHg) was 50 percent, averaging 10-12 mmHg over three years.

The company also released data showing 85 percent of patients are totally off glaucoma medication with a reduction in medication from 2.8 to 0.4 meds/patient at three years. The patients showed no long-term adverse events. None needed to be converted to trabeculectomy or large plate valves.

InnFocus has initiated Phase I Food and Drug Administration trials at 10 centers in the U.S.

The InnFocus MicroShunt provides a method of shunting aqueous humor from the anterior chamber to a diffuse bleb without the use of a scleral flap, using a micro-tube to control flow made from the SIBS material. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
© 2025 MJH Life Sciences

All rights reserved.